Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Michael Gnant; Georg Pfeiler; Günther G Steger; Daniel Egle; Richard Greil; Florian Fitzal; Viktor Wette; Marija Balic; Ferdinand Haslbauer; Elisabeth Melbinger-Zeinitzer; Vesna Bjelic-Radisic; Raimund Jakesz; Christian Marth; Paul Sevelda; Brigitte Mlineritsch; Ruth Exner; Christian Fesl; Sophie Frantal; Christian F Singer

doi:10.1016/S1470-2045(18)30862-3

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Michael Gnant
, Georg Pfeiler
, Günther G Steger
, Daniel Egle
, Richard Greil (Co-Autor/-in)
, Florian Fitzal
, Viktor Wette
, Marija Balic
, Ferdinand Haslbauer
, Elisabeth Melbinger-Zeinitzer
, Vesna Bjelic-Radisic
, Raimund Jakesz
, Christian Marth
, Paul Sevelda
, Brigitte Mlineritsch (Co-Autor/-in)
, Ruth Exner
, Christian Fesl
, Sophie Frantal
, Christian F Singer

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

185 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	339-351
Fachzeitschrift	LANCET ONCOL
Jahrgang	20
Ausgabenummer	3
DOIs	https://doi.org/10.1016/S1470-2045(18)30862-3
Publikationsstatus	Veröffentlicht - 2019

Zugriff auf Dokument

10.1016/S1470-2045(18)30862-3

Dieses zitieren

Gnant, M., Pfeiler, G., Steger, G. G., Egle, D., Greil, R., Fitzal, F., Wette, V., Balic, M., Haslbauer, F., Melbinger-Zeinitzer, E., Bjelic-Radisic, V., Jakesz, R., Marth, C., Sevelda, P., Mlineritsch, B., Exner, R., Fesl, C., Frantal, S., & Singer, C. F. (2019). Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET ONCOL, 20(3), 339-351. https://doi.org/10.1016/S1470-2045(18)30862-3

@article{7b7a50c2425947a9939021006c33f13f,

title = "Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.",

keywords = "PLUS ZOLEDRONIC ACID, CLINICAL-PRACTICE, BONE LOSS, THERAPY, WOMEN, BISPHOSPHONATES, INHIBITOR, RANKL, METAANALYSIS, PREVENTION",

author = "Michael Gnant and Georg Pfeiler and Steger, \{G{\"u}nther G\} and Daniel Egle and Richard Greil and Florian Fitzal and Viktor Wette and Marija Balic and Ferdinand Haslbauer and Elisabeth Melbinger-Zeinitzer and Vesna Bjelic-Radisic and Raimund Jakesz and Christian Marth and Paul Sevelda and Brigitte Mlineritsch and Ruth Exner and Christian Fesl and Sophie Frantal and Singer, \{Christian F\}",

note = "Greil: Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute–Centre for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute, Salzburg, Austria; Mlineritsch: Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute–Centre for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Salzburg, Austria ",

year = "2019",

doi = "10.1016/S1470-2045(18)30862-3",

language = "English",

volume = "20",

pages = "339--351",

journal = "LANCET ONCOL",

issn = "1470-2045",

publisher = "Elsevier ",

number = "3",

}

Gnant, M, Pfeiler, G, Steger, GG, Egle, D, Greil, R, Fitzal, F, Wette, V, Balic, M, Haslbauer, F, Melbinger-Zeinitzer, E, Bjelic-Radisic, V, Jakesz, R, Marth, C, Sevelda, P, Mlineritsch, B, Exner, R, Fesl, C, Frantal, S & Singer, CF 2019, 'Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.', LANCET ONCOL, Jg. 20, Nr. 3, S. 339-351. https://doi.org/10.1016/S1470-2045(18)30862-3

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. / Gnant, Michael; Pfeiler, Georg; Steger, Günther G et al.
in: LANCET ONCOL, Jahrgang 20, Nr. 3, 2019, S. 339-351.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

AU - Gnant, Michael

AU - Pfeiler, Georg

AU - Steger, Günther G

AU - Egle, Daniel

AU - Greil, Richard

AU - Fitzal, Florian

AU - Wette, Viktor

AU - Balic, Marija

AU - Haslbauer, Ferdinand

AU - Melbinger-Zeinitzer, Elisabeth

AU - Bjelic-Radisic, Vesna

AU - Jakesz, Raimund

AU - Marth, Christian

AU - Sevelda, Paul

AU - Mlineritsch, Brigitte

AU - Exner, Ruth

AU - Fesl, Christian

AU - Frantal, Sophie

AU - Singer, Christian F

N1 - Greil: Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute–Centre for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute, Salzburg, Austria; Mlineritsch: Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute–Centre for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Salzburg, Austria

PY - 2019

Y1 - 2019

KW - PLUS ZOLEDRONIC ACID

KW - CLINICAL-PRACTICE

KW - BONE LOSS

KW - THERAPY

KW - WOMEN

KW - BISPHOSPHONATES

KW - INHIBITOR

KW - RANKL

KW - METAANALYSIS

KW - PREVENTION

U2 - 10.1016/S1470-2045(18)30862-3

DO - 10.1016/S1470-2045(18)30862-3

M3 - Original Article

C2 - 30795951

SN - 1470-2045

VL - 20

SP - 339

EP - 351

JO - LANCET ONCOL

JF - LANCET ONCOL

IS - 3

ER -